| Abstrakt: |
A study conducted in the Czech Republic examined the real-world efficacy of venetoclax-based therapy in patients with acute myeloid leukemia (AML) who were unfit for intensive chemotherapy. The study included 162 newly diagnosed AML patients and found that the combination of azacitidine and venetoclax was highly effective, with comparable outcomes to published trial data. The research suggested that stopping treatment in low-risk, minimal residual disease-negative patients did not worsen overall survival, and patients with TP53 mutations benefited from treatment if they achieved complete remission within the first three cycles. [Extracted from the article] |
